{"id":"open-label-metformin","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3-5","effect":"Metallic taste"},{"rate":"10-30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and improving peripheral glucose uptake and utilization. It may also enhance insulin signaling and reduce intestinal glucose absorption, leading to improved glycemic control without stimulating insulin secretion.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:33.188Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07223671","phase":"PHASE1","title":"Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-12-31","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Advanced Solid Malignancies","enrollment":41},{"nctId":"NCT04530383","phase":"PHASE2","title":"Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function","status":"NOT_YET_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2026-04-15","conditions":"Cystic Fibrosis-related Diabetes, Cystic Fibrosis","enrollment":30},{"nctId":"NCT04930744","phase":"PHASE2","title":"Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2021-08-26","conditions":"Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection","enrollment":112},{"nctId":"NCT07368569","phase":"PHASE1","title":"A Study in Healthy People to Test Whether BI 764198 Influences the Amount of Metformin in the Body","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2026-02-06","conditions":"Healthy","enrollment":14},{"nctId":"NCT02365597","phase":"PHASE2","title":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2015-04-22","conditions":"Urothelial Cancer","enrollment":239},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT05013112","phase":"NA","title":"Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2023-01-01","conditions":"Kidney Transplantation, Metabolic Disorder, Metformin","enrollment":105},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07372625","phase":"PHASE1","title":"A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.","status":"RECRUITING","sponsor":"PMV Pharmaceuticals, Inc","startDate":"2026-02-04","conditions":"TP53 Y220C Mutation, Advanced Solid Tumors","enrollment":14},{"nctId":"NCT03006172","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2016-12-13","conditions":"Breast Cancer, Solid Tumor","enrollment":200},{"nctId":"NCT07066722","phase":"PHASE1","title":"A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2025-07-07","conditions":"HIV Infections","enrollment":126},{"nctId":"NCT07446400","phase":"PHASE1","title":"A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2026-03-20","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT07417306","phase":"PHASE3","title":"A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2026-03-27","conditions":"Type 2 Diabetes","enrollment":912},{"nctId":"NCT07412015","phase":"NA","title":"Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets","status":"NOT_YET_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2026-05-27","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":24},{"nctId":"NCT07158411","phase":"PHASE1","title":"Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)","status":"COMPLETED","sponsor":"Deciphera Pharmaceuticals, LLC","startDate":"2025-11-20","conditions":"Healthy Participants","enrollment":22},{"nctId":"NCT07222098","phase":"PHASE1","title":"A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-19","conditions":"Healthy","enrollment":16},{"nctId":"NCT07399470","phase":"PHASE1","title":"A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.","status":"ACTIVE_NOT_RECRUITING","sponsor":"LG Chem","startDate":"2026-01-09","conditions":"Healthy Volunteers, Fasting Conditions","enrollment":58},{"nctId":"NCT07396844","phase":"PHASE1","title":"The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"LG Chem","startDate":"2026-07-01","conditions":"Healthy, Fasting, Fed","enrollment":28},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT07372118","phase":"PHASE1","title":"Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-09-27","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":32},{"nctId":"NCT06881264","phase":"PHASE3","title":"A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-04-30","conditions":"Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","enrollment":401},{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT07120971","phase":"EARLY_PHASE1","title":"Metformin for Premature Infants With Bronchopulmonary Dysplasia","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-12-19","conditions":"Bronchopulmonary Dysplasia (BPD)","enrollment":40},{"nctId":"NCT07362030","phase":"PHASE1","title":"Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-04-14","conditions":"Obesity","enrollment":32},{"nctId":"NCT07342764","phase":"PHASE4","title":"Comparative Effectiveness of Dapagliflozin, Metformin, and Lifestyle Modification for Antipsychotic-Induced Weight Gain: An Open-Label Pragmatic Trial","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2026-04","conditions":"Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":120},{"nctId":"NCT06871761","phase":"PHASE3","title":"A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05-08","conditions":"Adult Patients With Type 2 Diabetes","enrollment":393},{"nctId":"NCT07333742","phase":"PHASE1","title":"A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal","status":"COMPLETED","sponsor":"LG Chem","startDate":"2025-09-29","conditions":"Fed Conditions, Healthy Volunteer","enrollment":50},{"nctId":"NCT07331389","phase":"PHASE1","title":"A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-09-24","conditions":"Overweight Subject, Healthy Subjects","enrollment":111},{"nctId":"NCT07216131","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-11-10","conditions":"Healthy Participants","enrollment":14},{"nctId":"NCT06504862","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-08-20","conditions":"Healthy","enrollment":32},{"nctId":"NCT00971243","phase":"PHASE2","title":"Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":448},{"nctId":"NCT07300007","phase":"PHASE1","title":"PK and Relative Bioavailability of Liquid Metformin vs Tablets in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Aspargo Labs, Inc","startDate":"2026-03-15","conditions":"Healthy Volunteer","enrollment":24},{"nctId":"NCT07275359","phase":"PHASE1","title":"Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-03-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT07266766","phase":"PHASE1","title":"Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-08-05","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":40},{"nctId":"NCT05064488","phase":"PHASE1","title":"Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-10-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT07266779","phase":"PHASE1","title":"Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-08-22","conditions":"Type 2 Diabetes","enrollment":36},{"nctId":"NCT04220021","phase":"PHASE2","title":"Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2020-01-10","conditions":"C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia","enrollment":41},{"nctId":"NCT07254572","phase":"PHASE4","title":"Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2025-07-10","conditions":"Coronary Artery Disease, PreDiabetes","enrollment":300},{"nctId":"NCT06688123","phase":"PHASE2","title":"Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-01-08","conditions":"Type 2 Diabetes","enrollment":275},{"nctId":"NCT04742751","phase":"PHASE2","title":"An Open-Label Pilot Intervention Trial to Prevent Diabetes in Prediabetic Adult Survivors of Childhood Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-03-02","conditions":"PreDiabetes, Adult Children","enrollment":96},{"nctId":"NCT06327815","phase":"PHASE4","title":"Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-03-15","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":633},{"nctId":"NCT07064486","phase":"PHASE3","title":"A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia","status":"RECRUITING","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2025-07-04","conditions":"Type 2 Diabetes (T2DM)","enrollment":477},{"nctId":"NCT06192108","phase":"PHASE3","title":"A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-10","conditions":"Type 2 Diabetes","enrollment":962},{"nctId":"NCT07121959","phase":"PHASE1","title":"A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-18","conditions":"Healthy","enrollment":14},{"nctId":"NCT07213895","phase":"PHASE1","title":"Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-05-21","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":14},{"nctId":"NCT05571319","phase":"PHASE2","title":"A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.","status":"COMPLETED","sponsor":"University of Stellenbosch","startDate":"2022-08-11","conditions":"Metabolic Syndrome, HIV Seropositivity","enrollment":30},{"nctId":"NCT05260021","phase":"PHASE3","title":"A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-04-13","conditions":"Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2","enrollment":99},{"nctId":"NCT06813924","phase":"PHASE1","title":"A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-02-06","conditions":"Healthy Volunteers Sickle Cell Disease, Thalassemia","enrollment":37},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT06045221","phase":"PHASE3","title":"A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-09-22","conditions":"Type 2 Diabetes","enrollment":1698},{"nctId":"NCT06257966","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2024-07-17","conditions":"Type2 Diabetes Mellitus","enrollment":600},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT06920056","phase":"PHASE1","title":"A Study of BGM0504 in Overweight or Obese Participants","status":"COMPLETED","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2025-03-24","conditions":"Overweight or Obese","enrollment":28},{"nctId":"NCT07093476","phase":"PHASE3","title":"Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","status":"RECRUITING","sponsor":"Celltrion","startDate":"2025-07-18","conditions":"T2DM, Diabete Type 2, DM","enrollment":171},{"nctId":"NCT06235086","phase":"PHASE3","title":"A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2024-04-08","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT05744479","phase":"PHASE4","title":"Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-02-28","conditions":"Intellectual Disability, Developmental Disability, Obesity","enrollment":100},{"nctId":"NCT06739044","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2023-09-20","conditions":"Type 2 Diabetes","enrollment":494},{"nctId":"NCT05929495","phase":"PHASE2","title":"Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma","status":"RECRUITING","sponsor":"University of Milano Bicocca","startDate":"2024-02-12","conditions":"Glioblastoma, IDH-wildtype, Metformin, Malignancies","enrollment":25},{"nctId":"NCT07083401","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fed)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-05","conditions":"Diabete Mellitus","enrollment":40},{"nctId":"NCT07083388","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fasting)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-03","conditions":"Diabetes Mellitus","enrollment":52},{"nctId":"NCT07061496","phase":"NA","title":"Comparative Effects of Exercise and Metformin on Glycemic Control in Prediabetic Adults","status":"NOT_YET_RECRUITING","sponsor":"Umair Ali","startDate":"2025-08-10","conditions":"Pre Diabetic, Pre Diabetes","enrollment":226},{"nctId":"NCT06161844","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-23","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT06085703","phase":"NA","title":"Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-04-01","conditions":"Type 2 Diabetes Mellitus, Mild Cognitive Impairment","enrollment":24},{"nctId":"NCT07057271","phase":"PHASE3","title":"A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues","status":"COMPLETED","sponsor":"Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","startDate":"2021-05-27","conditions":"Type 2 Diabetes Mellitus - Poor Control","enrollment":464},{"nctId":"NCT06679413","phase":"PHASE1","title":"A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2024-12-04","conditions":"Healthy Study Participants","enrollment":22},{"nctId":"NCT07044765","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study","status":"NOT_YET_RECRUITING","sponsor":"AJU Pharm Co., Ltd.","startDate":"2025-08","conditions":"Type2 Diabetes Mellitus","enrollment":32},{"nctId":"NCT06779253","phase":"PHASE1","title":"A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects","status":"COMPLETED","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2025-03-14","conditions":"Healthy Subjects","enrollment":39},{"nctId":"NCT04972396","phase":"PHASE1","title":"Pemvidutide (ALT-801) DDI Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2021-09-15","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":40},{"nctId":"NCT07034781","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"AJU Pharm Co., Ltd.","startDate":"2025-08","conditions":"Type2 Diabetes Mellitus","enrollment":50},{"nctId":"NCT06723691","phase":"PHASE1","title":"Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects","status":"COMPLETED","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2024-12-18","conditions":"Type 2 Diabetes","enrollment":57},{"nctId":"NCT07019012","phase":"PHASE4","title":"Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-07-30","conditions":"T2DM","enrollment":170},{"nctId":"NCT06649344","phase":"PHASE3","title":"A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2024-10-31","conditions":"Type 2 Diabetes","enrollment":884},{"nctId":"NCT04008186","phase":"PHASE1","title":"A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-06-14","conditions":"Healthy Adult Subjects","enrollment":61},{"nctId":"NCT06823856","phase":"PHASE1","title":"Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)","status":"COMPLETED","sponsor":"Gedeon Richter Plc.","startDate":"2025-05-11","conditions":"Diabetes Mellitus Type 2","enrollment":64},{"nctId":"NCT04090580","phase":"PHASE3","title":"Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin Versus Metformin Alone","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2019-10-27","conditions":"Type 2 Diabetes","enrollment":88},{"nctId":"NCT05680129","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-01-10","conditions":"T2DM, Type 2 Diabetes Mellitus","enrollment":623},{"nctId":"NCT06335134","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-07-14","conditions":"Healthy Volunteers","enrollment":57},{"nctId":"NCT06260722","phase":"PHASE3","title":"Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-02-21","conditions":"Diabetes Mellitus, Type 2","enrollment":1250},{"nctId":"NCT06766500","phase":"PHASE1","title":"Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)","status":"COMPLETED","sponsor":"Gedeon Richter Plc.","startDate":"2025-01-20","conditions":"Diabetes Mellitus Type 2","enrollment":64},{"nctId":"NCT06792968","phase":"PHASE1","title":"Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)","status":"COMPLETED","sponsor":"Gedeon Richter Plc.","startDate":"2025-03-30","conditions":"Diabetes Mellitus Type 2","enrollment":64},{"nctId":"NCT06793943","phase":"PHASE1","title":"A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-01-23","conditions":"Healthy Volunteers","enrollment":78},{"nctId":"NCT05828303","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"Turning Point Therapeutics, Inc.","startDate":"2024-11-15","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":""},{"nctId":"NCT04288778","phase":"PHASE4","title":"A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes","status":"COMPLETED","sponsor":"Johnson & Johnson Private Limited","startDate":"2020-11-25","conditions":"Diabetes Mellitus","enrollment":276},{"nctId":"NCT06452511","phase":"EARLY_PHASE1","title":"Comparing the Effect of Metformin vs. Pep2dia as an Adjunct to Letrozole on Ovulation Induction and Pregnancy Outcomes in Overweight Women With PCOS","status":"COMPLETED","sponsor":"Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy","startDate":"2024-08-01","conditions":"PCOS","enrollment":100},{"nctId":"NCT06863532","phase":"NA","title":"Efficacy and Safety Comparison of Cofrogliptin Add-on Versus Metformin Dose-escalation in Type 2 Diabetes Patients Inadequately Controlled With SGLT-2 Inhibitors Plus Low-Dose Metformin:A Multicenter, Open-Label Trial","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-30","conditions":"Type 2 Diabetes","enrollment":80},{"nctId":"NCT06227832","phase":"PHASE1","title":"A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants","status":"COMPLETED","sponsor":"Kaken Pharmaceutical","startDate":"2023-12-15","conditions":"Healthy Adults","enrollment":38},{"nctId":"NCT06655220","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether BI 1815368 Influences the Amount of Metformin in the Body","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-11-08","conditions":"Healthy","enrollment":14},{"nctId":"NCT05550129","phase":"PHASE1","title":"Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-11-13","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT03989778","phase":"PHASE2","title":"Vitamin D and Polycystic Ovarian Syndrome (PCOS)","status":"RECRUITING","sponsor":"Aga Khan University","startDate":"2023-02-01","conditions":"Infertility, Female, Infertility, Vitamin D Deficiency","enrollment":300},{"nctId":"NCT06045351","phase":"PHASE1","title":"Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome","status":"RECRUITING","sponsor":"Aga Khan University","startDate":"2024-01-01","conditions":"Anovulatory Infertility","enrollment":142},{"nctId":"NCT06716216","phase":"PHASE3","title":"A Study of BGM0504 in Participants with Type 2 Diabetes","status":"RECRUITING","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2024-11-29","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":537},{"nctId":"NCT06473662","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects","status":"COMPLETED","sponsor":"Roger New","startDate":"2018-10-22","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":153},{"nctId":"NCT06416800","phase":"PHASE1","title":"A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-06-19","conditions":"Healthy Participants","enrollment":71},{"nctId":"NCT02851095","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08","conditions":"Healthy","enrollment":44},{"nctId":"NCT02865668","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08","conditions":"Healthy","enrollment":44},{"nctId":"NCT02611518","phase":"PHASE1","title":"A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-04-05","conditions":"Healthy","enrollment":32},{"nctId":"NCT02846506","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08","conditions":"Healthy","enrollment":44},{"nctId":"NCT06523595","phase":"PHASE1","title":"Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2024-07-31","conditions":"Pain","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fortamet®","Glucophage®","Glucophage® XR","Glumetza®","Riomet®"],"phase":"phase_3","status":"active","brandName":"Open-label Metformin","genericName":"Open-label Metformin","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK). Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}